Cite
HARVARD Citation
Kushner, B. et al. (n.d.). A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long‐term progression‐free survival of patients with resistant neuroblastoma. International journal of cancer. 140 (2), pp. 480-484. [Online].